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ABSTRACT: About a half a century has passed
since dopamine was identified as a neurotransmitter,
and it has been several decades since it was estab-
lished that people with Parkinson’s disease receive
motor symptom relief from oral levodopa. Despite the
evidence that levodopa can reduce motor symptoms,
there has been a developing body of literature that
dopaminergic therapy can improve cognitive functions
in some patients but make them worse in others. Over
the past two decades, several laboratories have shown
that dopaminergic medications can impair the action of
intact neural structures and impair the behaviors asso-
ciated with these structures. In this review, we consider
the evidence that has accumulated in the areas of
reversal learning, motor sequence learning, and other
cognitive tasks. The purported inverted-U shaped rela-
tionship between dopamine levels and performance is
complex and includes many contributory factors. The
regional striatal topography of nigrostriatal denervation
is a critical factor, as supported by multimodal neuroi-
maging studies. A patient’s individual genotype will
determine the relative baseline position on this inverted-
U curve. Dopaminergic pharmacotherapy and individual
gene polymorphisms can affect the mesolimbic and
prefrontal cortical dopaminergic functions in a compara-
ble, inverted-U dose-response relationship. Depending
on these factors, a patient can respond positively or
negatively to levodopa when performing reversal learn-
ing and motor sequence learning tasks. These tasks
may continue to be relevant as our society moves to
increased technological demands of a digital world that
requires newly learned motor sequences and adaptive
behaviors to manage daily life activities. VC 2013 Interna-
tional Parkinson and Movement Disorder Society
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A little over half a century has passed since dopa-
mine was identified as a neurotransmitter and it was
recognized that depleting monoamines in the brain
through the administration of reserpine caused
hunched immobility in rodents.1 This finding led to
the hypothesis of a dopaminergic depletion disorder as
the pathophysiological basis of Parkinson’s disease.
Since then, dopamine substitution using (L-3,4-dihy-
droxyphenylalanine [L-dopa]) has been the most
widely used pharmacotherapy for Parkinson’s disease.
Despite reducing symptom manifestation, a majority
of patients chronically exposed to dopamine therapy
will eventually develop motor complications, including
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response fluctuations and drug-induced dyskinesias
(abnormal, involuntary movements), such as choreic
and dystonic limb or truncal movements.2 In addition,
while restoring cognitive functions associated with
dopamine-depleted brain regions, dopamine substitu-
tion can also impair certain cognitive functions, such
as probabilistic reversal learning, motor sequence
learning, and other cognitive tasks, that are associated
with intact dopamine-dependent brain regions.3–5
Dopamine overstimulation has been studied for over a
decade since the work of Gotham and colleagues,6
and the articles by Swainson and colleagues7 and
Cools and colleagues3 initially proposed the dopamine
overdose hypothesis.
Fronto-executive cognitive deficits can be observed
even in early Parkinson’s disease in the areas that
include executive function, learning, memory, motor
inhibition, impulse control, and visuospatial process-
ing.8 These cognitive deficits may be related to meso-
cortical, mesolimbic, and nigrostriatal dopaminergic
pathways as well as other pathways associated with
acetylcholine and norepinephrine.8 Cognitive deterio-
ration after dopaminergic therapy can occur in several
tasks. In this review of the dopamine overdose hypoth-
esis, we characterize the specific evidence supporting
this hypothesis by reviewing the relevant literature in
the areas of reversal learning, motor sequence learn-
ing, and other cognitive tasks. Issues related to impul-
sivity and reward processing are not addressed in this
review, because these issues have been addressed pre-
viously.9,10 First, we discuss the physiology of the
dopamine overdose hypothesis. Next, we discuss evi-
dence for the negative effects of dopaminergic medica-
tion on probabilistic reversal learning, followed by the
evidence for the negative effects of dopaminergic med-
ication on motor sequence learning. We then discuss
the evidence that other cognitive tasks can be nega-
tively affected by L-dopa when patients with Parkin-
son’s disease carry specific genetic polymorphisms.
Finally, we discuss the clinical implications of the
hypothesis as they apply to the treatment and manage-
ment of patients with Parkinson’s disease.
Physiological Basis for the Dopamine
Overdose Hypothesis
There are two major subtypes of dopaminergic neu-
rons in the brain: the neurons of the substantianigra
pars compacta (A9 neurons)11,which give rise to the
nigrostriatal pathway, and the A10 neurons of the
ventral tegmental area (VTA), which give rise to the
mesolimbic and mesocortical pathways that innervate
parts of the limbic system and the neocortex.12 The
regional pattern of degeneration within the substantia
nigra in patients with Parkinson’s disease appears to
be specific, such that a loss of pigmented neurons is
greatest in the ventral lateral tier, followed by the dor-
sal tier, which is different to the patterns identified
with healthy aging.13 In vivo diffusion magnetic reso-
nance imaging (MRI) has provided evidence in sup-
port of this selective pattern of degeneration by
showing that measures of structural integrity within
the ventral and lateral substantia nigra are most
affected in early Parkinson’s disease compared with
control subjects,14,15 whereas the dorsal substantia
nigra is affected more in older adults than in young
adults.16
The ventral lateral tier of the substantia nigra sends
dopaminergic projections primarily to the dorsal puta-
men, whereas the dorsal tier of the substantia nigra
sends dopaminergic projections primarily to the ven-
tral striatum. The ventral striatum also receives projec-
tions from the VTA.11 Studies using 18F-dopa positron
emission tomography (PET) have demonstrated that
patients with unilateral Parkinson’s disease who are in
Hoehn and Yahr stage 1 have reduced dopamine stor-
age primarily within the dorsal putamen contralateral
to motor symptoms.17 In a cross-sectional study, it
was demonstrated that, in early Parkinson’s disease,
18F-dopa metabolism was reduced by almost 50% in
the dorsal rostral putamen and dorsal caudal putamen,
whereas the ventral putamen was unaffected.18 With
the progression of disease symptoms, there is a loss of
18F-dopa metabolism in the ventral putamen. Longitu-
dinal multitracer PET studies have demonstrated that
the posterior-dorsal to anterior-ventral striatal gradi-
ent of nigrostriatal denervation is maintained, whereas
the asymmetry gradient becomes less prominent with
progressive Parkinson’s disease.19 Figure 1A illustrates
the posterior-dorsal to anterior-ventral gradient of
nigrostriatal denervation in Parkinson’s disease across
different stages of disease severity (from mild to
severe, left to right). Early and most severe loss of
nerve terminals is in the dorsal and posterior putamen.
Anterior and ventral striatal regions are relatively
spared, at least in the early stage of disease. This pat-
tern of striatal degeneration from dorsal to ventral
segments with the progression of Parkinson’s disease
provides a fundamental basis for the dopamine over-
dose hypothesis. That is, regions that are less affected
early in the disease could be over stimulated by exoge-
nous dopamine administration.
It has been several decades since Cotzias and col-
leagues20 demonstrated the striking efficacy of oral
L-dopa for relieving motor symptoms of Parkinson’s
disease. Since that time, L-dopa has remained the gold
standard for antiparkinsonian therapy. Nonetheless,
because the dorsal putamen is mostly affected in early
Parkinson’s disease, whereas the ventral striatum
remains relatively intact,18 a given dose of L-dopa that
has beneficial effects for most motor tasks that rely
upon the dorsal putamen can also have deleterious
effects on specific cognitive and motor tasks that spe-
cifically rely upon the ventral striatum.5 The adminis-
tration of L-dopa is thought to decarboxylase in
D O P A M I N E O V E R D O S E H Y P O T H E S I S
Movement Disorders, Vol. 28, No. 14, 2013 1921
remaining dopaminergic neurons; thus, the lack of
specificity of dopamine therapy can lead to a possible
over stimulation of ventral striatal areas that remain
intact. Figure 1B illustrates the many factors that can
modulate the effects of dopaminergic medication on
performance, including disease stage, striatal structure
engaged by the task, and genotype for genes that regu-
late endogenous dopamine availability. The dopamine
overdose hypothesis proposes that, when patients with
Parkinson’s disease are off L-dopa or other dopaminer-
gic medications, their performance on tasks like prob-
abilistic reversal learning is optimal, whereas their
performance on cognitive tasks like set-switching is
impaired. Because reversal learning and set-switching
implicate the ventral and dorsal striatum, respec-
tively,21,22 these tasks have provided excellent para-
digms to investigate dopaminergic effects on different
striatal regions. Furthermore, when L-dopa or other
dopaminergic medications are given to the patient, the
proposal is that performance on probabilistic reversal
learning will worsen, but set-switching performance
improves. Whereas set-switching requires flexible
swapping or switching between tasks, reversal learning
requires an adaptation to a previously learned
stimulus-reward contingency. The central tenet of the
dopamine overdose hypothesis is that tasks that rely
on the ventral striatum will be impaired by dopami-
nergic medications in early Parkinson’s disease because
of overstimulation of the structure.
In addition to the effects of dopamine on the ventral
and dorsal striatum, there is also evidence that dopa-
mine overdose effects can occur in prefrontal cortex.8
The mesocortical dopaminergic pathway projects from
the VTA to the frontal cortex, and this pathway regu-
lates numerous cognitive functions, including set-
shifting, working memory, and planning. As reviewed
in subsequent sections, the studies in the literature col-
lectively point to a cortical and subcortical role for
dopamine overdose effects. In the next sections, we
review the specific evidence in support of the dopa-
mine overdose hypothesis in several domains of learn-
ing and cognitive performance.
FIG. 1. (A) The posterior-dorsal to anterior-ventral gradient of nigrostriatal denervation is illustrated in Parkinson’s disease (PD) across different
stages of severity of disease (from mild to severe; left to right). Early and most severe loss of nerve terminals is in the dorsal and posterior putamen
(P). Anterior and ventral striatal regions are relatively spared, at least in early stage of disease. C indicates caudate. (B) Individual patients can expe-
rience differing performance effects in response to levodopa (L-DOPA) administration because of a combination of factors, including stage of dis-
ease, striatal structure used in the task, and genotype for genetic polymorphisms that play a role in dopaminergic metabolism in the striatum and
prefrontal cortex (Cools 20065). These factors collectively determine each patient’s starting location on the inverted-U shaped function describing
the association between dopamine (DA) and performance, which, in turn determines whether performance will worsen, improve, or show no change
with dopaminergic medications. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
V A I L L A N C O U R T E T A L .
1922 Movement Disorders, Vol. 28, No. 14, 2013
Reversal Learning and Dopamine in
Parkinson’s Disease
Table 1 provides a summary of the studies that have
investigated reversal learning paradigms in patients
with Parkinson’s disease off and on L-dopa. The con-
sistent empirical finding has been that, when patients
are on L-dopa, reversal learning performance is
impaired compared with their performance off L-dopa.
Initial evidence in support of this finding was from a
study by Swainson and colleagues.7 Those authors
studied three groups of patients with Parkinson’s dis-
ease, including mild/unmedicated, mild/medicated, and
severe/medicated patients. The reversal learning task
required patients to choose between a red pattern and
a green pattern, with one pattern rewarded over the
other on a probabilistic schedule. The participants
were asked to learn the task and figure out which pat-
tern was correct; and, after a series of trials, the cor-
rect pattern was reversed. This was not immediately
detectable, given that rewards were assigned probabil-
istically (eg, 80:20 ratio). When the reversal occurred,
patients in the mild/medicated and severe/medicated
groups had difficulty adapting to the new pattern;
however, patients in the mild/unmedicated group had
no difficulty adapting in the reversal learning task. In
a subsequent study by the same laboratory,3 set-
switching performance and reversal learning were
compared in two groups of patients with Parkinson’s
disease while either off or on dopaminergic therapy.
The set-switch task required patients to identify the
correct letter or number in a well learned sequence
and did not require them to adapt to a new condition
as in the reversal learning task. The authors observed
that reaction time during the set-switch task was
reduced with dopaminergic medication. During the
reversal learning task, patients with Parkinson’s dis-
ease in the off and on medication groups made more
errors than control participants at the reversal learning
stage, but the patients with Parkinson’s disease who
were off medication were able to adapt to the reversal.
Patients on dopaminergic medication had more diffi-
culty shifting their performance when the reward stim-
uli reversed. Although the between-group design used
in those studies may have made interpretations diffi-
cult, they did provide a critical advance in identifying
which type(s) of task is detrimentally affected by
dopaminergic medication in mild to moderate Parkin-
son’s disease.
Subsequent studies by the same laboratory and
others have used within-subjects designs to test
patients with Parkinson’s disease off and on L-dopa.
Fifteen patients with Parkinson’s were tested off and
TABLE 1. Summary of studies in which probabilistic learning and motor sequence learning paradigms have been investi-
gated in patients with Parkinson’s disease off and on L-dopa
Study Outcome Measure Results
Swainson et al. 20007 Probabilistic reversal learning Medicated PD groups showed impairments on reversal learning tasks
Cools et al. 20013 Probabilistic reversal learning Dopamine medication induced impairment in reversal stage of learning task
Shohamy et al. 2006 31 Probabilistic category learning Impairment in initial learning, but not transfer, of association between stimuli and
rewards
Cools et al. 200664 Deterministic reversal learning Dopaminergic medication-induced deficits on reversal shifting were restricted to
reversals signaled by unexpected punishment but not by unexpected reward
Funkiewiez et al 200665 Probabilistic reversal learning L-Dopa impaired performance on the extinction phase of reversal learning task
Cools et al. 200766 Probabilistic reversal learning L-Dopa disrupted activity in the nucleus accumbens but not in the dorsal striatum
or prefrontal cortex during reversal learning
Graef et al. 201027 Probabilistic reversal learning Reward based reversal learning with changing reward contingencies was impaired
with dopamine medication
Feigin et al 200349 Motor sequence learning L-Dopa infusion had no effect on motor sequence learning
Carbon and Eidelberg 200648 Motor sequence learning L-Dopa decreased measures of network activity and learning task performance in
PD patients
Ghilardi et al 200751 Motor sequence learning L-Dopa improved scores on simple motor tasks and movement speed but had no
effect on motor sequence learning
Argyelan et al. 200852 Motor sequence learning In de novo patients, L-dopa suppressed learning-related deactivation of the ventro-
medial prefrontal cortex
Kwak et al. 20104 Motor sequence learning Dopamine medication selectively impaired early-phase motor sequence learning
Kwak et al. 201244 Motor sequence learning L-Dopa decreased ventral striatum activation during the early learning phase;
extent was correlated with L-dopa–associated reductions in motor sequence
learning
Kwak et al. 201343 Motor sequence learning Improved sequence learning only for patients carrying the minor T allele for a
DRD2 polymorphism
Kwak et al. 201353 Motor sequence learning Spatial pattern of nigrostriatal dopaminergic denervation predicted L-dopa–associ-
ated impairments in motor sequence learning
PD, Parkinson’s disease; L-dopa, levodopa; DRD2, dopamine receptor D2.
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on L-dopa monotherapy using an instrumental learning
task with constant stimulus-reward associations and a
reversal learning task that had changing reward con-
tingencies. The study counterbalanced whether
patients were tested in the on or off state first. A sim-
ple instrumental learning task was used, because it has
been linked mainly with dorsal striatum and frontal
circuits,23,24 whereas the reversal learning task has
been linked with ventral striatum and frontal cir-
cuits.21,25,26 The prediction was that dopaminergic
medication would have opposite effects on perform-
ance during these two tasks. Figure 2 illustrates exper-
imental findings from the study during the
instrumental learning task and the reversal learning
task.27 During the instrumental learning task (Fig.
2A), which had constant reward contingencies,
patients on L-dopa produced a greater percentage of
correct choices compared with when they were off
L-dopa. Figure 2B illustrates the opposite pattern for
the reversal learning task. Here, patients on L-dopa
produced fewer reversal errors than when they were
off medication. These findings controlled for the test-
ing order and tested the same patients, and the results
provide compelling evidence that reversal learning is
impaired when patients with Parkinson’s disease are
on medication.
Another probabilistic learning task, which was
developed by Gluck and colleagues, is the weather
prediction task.28 In this task, four cards have inde-
pendent and probabilistic relationships to two possible
outcomes: sun and rain. Patients with Parkinson’s dis-
ease exhibit impaired learning on this task when they
are on dopaminergic medication, but they learn at a
rate similar to that of controls when off medica-
tion.29,30 In a similar paradigm, Parkinson’s patients
and a group of controls were asked to learn which of
two stimuli was associated with a reward.31 The stim-
uli varied in shape and color, with only dimension
predicting reward. The patients with Parkinson’s dis-
ease were impaired at learning the initial association
when on medications, but not when they were off
medications. In the next phase of the study, the rele-
vant dimension of each stimulus was held constant,
whereas the irrelevant feature changed. The control
group, the on-medication Parkinson’s group, and the
off-medication Parkinson’s group all performed
equally well during this transfer phase. Because it has
been shown that the weather prediction task relies on
the head caudate nucleus32 (a more anterior striatal
structure that exhibits dopaminergic denervation later
in Parkinson’s disease than the putamen), these find-
ings provide additional support that the dopamine
overdose hypothesis plays a role in the behavior of
patients with Parkinson’s disease when they are on
L-dopa.
Dopamine stimulates receptors in the basal ganglia
and prefrontal cortex, and there is an important dis-
tinction for D1 and D2 receptors in these brain
regions. The dopamine overdose hypothesis is also
supported from studies of dopamine synthesis in ani-
mals and pharmacological studies in healthy adults. In
animal models, stimulating D1 receptors with dopami-
nergic medication in the prefrontal cortex has revealed
changes in the firing of neurons during the delay
period of delayed-response tasks.33–35 Computational
models have provided insight into how dopamine
enhances D1 receptor stimulation such that dopamine
can increase the resistance to distracting stimuli.36,37
D2 receptors are more abundant in the basal ganglia
than in the prefrontal cortex, and it has been sug-
gested that the basal ganglia may serve as a gating
mechanism for updating the prefrontal cortex.38 D2
FIG. 2. (A) Performance in the on-beginner (“on first”) and off-beginner (“off first”) subgroups is illustrated across sessions on the reversal learning
task. Covariate-corrected estimated means of the number of reversals achieved are shown in boxes. (B) Performance in the on-beginner (“on first”)
and off-beginner subgroups (“off first”) is illustrated across sessions on the instrumental learning task. Covariate-corrected estimated means of per-
centage of correct choices are shown in boxes (adapted from Graef and colleagues 201027). [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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receptor stimulation has been tested in healthy adults
using the D2 receptor agonist bromocriptine relative
to their baseline dopamine synthesis capacity as deter-
mined by 18F-fluoro-L-meta-tyrosine PET tracer.39
Individuals performed a reward-based reversal learn-
ing task with deterministic stimulus-outcome contin-
gencies that required a button press to predict whether
the face or scene stimulus would lead to a reward or
punishment. The authors observed that, in a placebo
test, striatal dopamine synthesis was positively related
to reversal learning performance. Individuals with low
striatal dopamine synthesis performed poorly on the
reversal learning task, whereas high striatal dopamine
synthesis was associated with high reversal learning
performance. The participants with low striatal dopa-
mine synthesis responded positively to bromocriptine.
In contrast, participants with high baseline striatal
dopamine synthesis were over stimulated by bromoc-
riptine and exhibited impaired reversal learning per-
formance when on the drug.
In a study using event-related functional MRI
(fMRI), it was observed that, in healthy adults per-
forming a probabilistic reversal learning task, the ven-
tral striatum and ventrolateral prefrontal cortex were
specifically activated when individuals committed
reversal errors.21 A recent study evaluated the effects
of bromocriptine versus sulpiride (a D2 receptor
antagonist) and the combination of both drugs on
reward and punishment reversal learning.40 It was
found that improved reward relative to punishment
reversal learning performance occurred with the
administration of sulpiride compared with bromocrip-
tine. These findings provide additional insight into the
specificity of the D1 and D2 receptors related to
reward and punishment during reversal learning.40
Next, we discuss the pertinent findings for the dopa-
mine overdose hypothesis in relation to motor
sequence learning.
Motor Sequence Learning and Dopamine in
Parkinson’s Disease
Both probabilistic reversal learning and category
learning rely on more ventral subcortical structures,
such as the nucleus accumbens and caudate nucleus,
which remain relatively intact in mild to moderate
Parkinson’s disease. Thus, the dopamine overdose
hypothesis provides a plausible framework from which
to interpret the finding that patients perform these
tasks better when off medication. There is a gradient
of dopaminergic denervation within the caudate and
putamen as well, with the more ventral and anterior
portions of these structures affected later in the dis-
ease.41,42 The Seidler laboratory has conducted a
series of experiments to investigate interactions
between this gradient of denervation and anti-
parkinsonian medications working with a motor
sequence learning task.4,43,44
Motor sequence learning refers to the capacity to
combine individual elements of action into one
smooth, cohesive movement. For example, patients
moving into an assisted-living facility may need to
learn an action sequence to navigate their new sur-
roundings. Sequential behavior is also important for
skills like driving and playing a musical instrument,
and motor sequence learning plays an important role
in many physical rehabilitation protocols. In healthy
individuals, it is known that the process of motor
sequence learning relies on the striatum.45–47 In partic-
ular, it has been demonstrated that, early in sequence
learning, the more ventral and anterior portions of the
striatum (ie, associative striatum) are engaged47;
whereas, once a sequence becomes well learned, it is
represented in the more dorsal and posterior aspects
of the striatum (ie, sensorimotor striatum). Previous
studies investigating the effects of medication on
sequence learning in Parkinson’s patients have yielded
mixed results. Table 1 includes the study by Carbon
and Eidelberg,48 which references data from two prior
studies from the same laboratory indicating that
motor sequence learning was impaired by L-dopa. The
initial article by Feigin and colleagues49 indicated that
L-dopa reduced sequence learning in Parkinson’s
patients for a subjective measure of self-reported
learning. When comparing objective measures, those
investigators reported nonsignificant differences in
sequence learning for patients on versus off
L-dopa.50,51 Although not significant for objective
measures of learning, the direction of change was an
indication that L-dopa may be impairing sequencing
learning for some individuals—the opposite of the
effects observed with deep brain stimulation, which
improved sequencing learning.48,49 This line of work
averaged performance across time rather than examin-
ing performance changes in the context of learning.
Based on the purported inverted-U–shaped relation-
ship between dopamine levels and performance and
the established changes in associative and sensorimo-
tor striatum with learning, it is possible that Parkin-
son’s patients learned new motor sequences faster in
the early stages of learning when they were off
medication compared with their speed of learning on
medication. In contrast, once sequences become well
learned, patients may be able to perform them better
when on medication as opposed to off medication.
In an initial experiment,4 14 patients with mild to
moderate Parkinson’s disease and 11 healthy controls
within the same age range were evaluated for their abil-
ity to learn a sequence of finger movements. Patients
were tested on two separate occasions: once on their
anti-parkinsonian medications, which included various
combinations of medications across the participants of
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L-dopa and/or dopamine agonists; and, on the second
occasion, patients were tested in the functional off state
12 to 18 hours after taking their last dose of dopaminer-
gic medications. Testing occurred in a counterbalanced
fashion across medication states. As predicted by the
dopamine overdose hypothesis, patients off medication
exhibited early learning improvements that were equiv-
alent to those of control participants for the early phase
of learning (see Fig. 3A). As learning progressed, per-
formance of the patients on medication began to catch
up to that of their off-medication performance.
In a follow up study,44 new cohorts of 17 Parkin-
son’s patients and 21 healthy controls were studied to
evaluate brain networks after being recruited during
sequence learning with fMRI. Again, patients were
tested across two different days. For this study, a
single-blind, placebo-controlled medication design was
used, and patients were given either L-dopa plus carbi-
dopa or placebo plus carbidopa after arriving for the
study in the functional off state. The order of drug
versus placebo testing was counterbalanced across
testing days. It was observed that L-dopa was associ-
ated with decreased recruitment of the ventral puta-
men during the early phase of sequence learning.
Moreover, the difference in activation levels in this
structure between on-medication and off-medication
testing days was correlated with differences in
sequence learning performance between on and off
days across individual patients. That is, patients who
had the largest decrease in ventral putamen activation
when on medication versus off medication exhibited
the largest decrease in sequence learning abilities when
on medication versus off medication, as illustrated in
Figure 3B. A PET investigation by another group
reported reduced brain deactivation when Parkinson’s
patients were learning a sequence of actions on versus
off L-dopa.52 Taken together, these findings suggest
that both task-relevant and default network activation
can be negatively impacted by the administration of
L-dopa in mild to moderate stage Parkinson’s disease.
Another study measured dopaminergic denervation
in 18 Parkinson’s patients using 11C-dihydrotetrabena-
zine PET scans.53 Patients acquired new motor
sequences on two testing days in a counterbalanced
within-subjects design on either placebo or L-dopa
plus carbidopa. The ratio of denervation in the ante-
rior putamen versus the posterior dorsal putamen pre-
dicted the level of L-dopa–associated impairments in
motor sequence learning. That is, patients who had
relatively less denervation in the anterior putamen
exhibited greater on-medication sequence learning dec-
rements. Thus, individual differences in the magnitude
of motor sequence learning dopamine overdose effects
can be predicted by the spatial pattern of dopaminer-
gic denervation across the striatum.
Genotype and Dopaminergic Medication
Interact to Influence Cognitive Function
Another set of studies indicates that dopaminergic
medication may lead to deleterious performance on
specific cognitive tasks, depending on the genotype of
FIG. 3. (A) Patients off their medication learn new sequences of action at the same rate as healthy controls, whereas patients on medication are
impaired. For trials 1 through 16 and 49 through 64, participants pressed buttons in response to randomly cued stimuli; trials 17 through 48 were
sequence practice trials (from Kwak et al. 20104). (B) A region in the right ventral putamen is illustrated that is more active when patients learn a
motor sequence off medication than when they are on medication. This differential activation is correlated with off-medication improvements in
sequence learning (from Kwak et al. 201343). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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the patient (Fig. 1B). A common polymorphism in the
catechol O-methyltransferase (COMT) gene has a
strong influence on performance on tests of working
memory, attention, and planning.54–56 COMT is an
important regulator of dopamine levels, and it is
believed that its activity primarily influences dopamine
levels in the prefrontal cortex.57,58 In healthy individu-
als,59 low-activity COMT genotypes are associated
with improved performance on the Wisconsin Card
Sorting Test, and fMRI studies have confirmed that
prefrontal cortex activity is influenced by the COMT
genotype. However, performance on a Tower of Lon-
don cognitive test in a large cohort of 288 patients
with Parkinson’s disease indicated that low COMT
activity was associated with impaired performance,
and the effect was more pronounced in those patients
who were taking dopaminergic medications.54 Using
fMRI, it was observed that patients with Parkinson’s
disease who were homozygous for valine (val/val; high
COMT activity) performed better and had greater
activity in the frontal-parietal cortex compared with
patients with Parkinson’s disease who were homozy-
gous for methionine (met/met; low COMT activity).56
The authors did not find clear fMRI differences in the
putamen or caudate nucleus.
In a task of attention control,55 a group of patients
with Parkinson’s disease who tested positive for the
high COMT genotype (val/val) adopted a more opti-
mal attention shifting strategy compared with a group
who had Parkinson’s disease with the low COMT
genotype (met/met). The low-COMT genotype group
failed to adopt the attention shifting strategy. The
authors also observed that the fronto-parietal network
typically associated with attention was less active in
the low-COMT genotype group compared with the
high-COMT genotype group. There were no differen-
ces observed in the putamen or caudate nucleus.
Another gene that may interact with medication
effects in Parkinson’s patients is the DRD2 gene,
which codes for dopamine D2 receptors in the stria-
tum. A recent study43 evaluated whether a particular
DRD2 polymorphism (reference single nucleotide
polymorphism rs1076560; G>T) was associated with
the on-medication versus off-medication sequence
learning effects that were previously reported in
patients with Parkinson’s disease. DRD2 T allele car-
riers of this polymorphism have reduced D2S expres-
sion (short isoform of the D2 receptor) compared with
G allele carriers, who have higher D2 receptor avail-
ability. It was predicted that patients with Parkinson’s
disease who were minor T allele carriers would exhibit
a greater benefit of L-dopa on early stage sequence
learning. This hypothesis was evaluated in a behav-
ioral study with 45 patients who had Parkinson’s dis-
ease, including 1 patient who had the TT genotype
(grouped together with GT patients), 10 who had the
GT genotype, and 34 who had the GG genotype.
Patients were tested on two days according to a
single-blind, placebo-controlled design. L-Dopa
improved early sequence learning over the level of pla-
cebo pill only for the TT and GT patients, whereas
GG patients did not learn better on L-dopa. In con-
trast, L-dopa improved performance on the grooved
pegboard test, a simple motor execution test that
should rely predominately on the sensorimotor stria-
tum, for all patients regardless of genotype.
These findings suggest that endogenous dopamine-
modulating factors and exogenous dopamine interact
to result in dopamine overdose effects in patients with
Parkinson’s disease. That is, disease, genetics, and
medication status can all influence an individual’s
location on the inverted-U–shaped function relating
dopamine to performance. Moreover, these studies
suggest that the viewpoint that the dopamine overdose
hypothesis occurs only because of the ventral and dor-
sal striatum is too narrow and that other factors,
including the prefrontal and parietal cortices, also play
a role. In addition, these findings further demonstrate
that it is important to consider the genotype of the
patient when interpreting the effects of dopamine on
cognitive functions.
Clinical Implications and Conclusions
The clear consensus of a large body of literature is
that dopaminergic therapy can improve cognitive func-
tions in some patients but makes them worse in others
(for an in-depth review, see Cools5). The dopamine
overdose hypothesis provides a conceptual framework
to better understand patients’ individual cognitive
responses to dopaminergic pharmacotherapy in Par-
kinson’s disease. The purported inverted-U–shaped
relationship between dopamine levels and performance
is complex and includes many contributory factors. As
discussed in this review, the regional striatal topogra-
phy of nigrostriatal denervation is a critical factor, as
supported by fMRI and dopaminergic PET studies.
Second, a patient’s individual genotype will determine
the relative baseline position on this inverted-U curve.
Third, dopaminergic pharmacotherapy and individual
gene polymorphisms, such as COMT, can also affect
the mesolimbic and prefrontal cortical dopaminergic
functions in a comparable inverted-U dose-response
relationship, similar to what has been proposed for
the striatum. Therefore, currently, a patient’s individ-
ual cognitive response to dopaminergic pharmacother-
apy cannot be predicted by a simple formula.
However, several clinical implications may be inferred
based on the available literature and experience in
clinical movement disorders practice.
Striatal dopamine overdose effects have been identi-
fied for probabilistic reversal learning and motor
sequence learning tasks. Implications for instrumental
activities of daily living are clearly apparent. Current
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technological advances in society will affect individuals
who are living with Parkinson’s disease. Exposure to
new electronic gadgets for daily communication, finan-
cial management, bill paying, receiving health care, and
even medication management are essentially unavoid-
able and will challenge patients’ learning skill abilities.
This will include sequential motor behaviors like fine
and precise finger movements when using these new
gadgets. Navigation in new environments, whether it is
driving a car in new surroundings or moving into a
new place to live, will be equally challenging.
A key predictor for adverse cognitive learning effects
of dopaminergic therapy is the presence of early stage
and/or mild severity of disease, in which overdose
effects of dopaminergic medications are predicted to
be most prominent. Practical implications of the dopa-
mine overdose hypothesis in the management of the
individual patient with Parkinson’s disease will depend
first on the identification of a dopaminergic dose-
related cognitive or behavioral problem. If such a
problem is present, then a simple pointer will be to
implement a new motor learning challenge, such as
using a new device, when in a relative medication off
state (assuming preservation of critical motor abil-
ities). Apart from learning new motor behaviors in an
off state, a rational pharmacological therapy approach
based on the principle of the lowest effective dose also
may help to prevent or ameliorate dopaminergic on
overdose cognitive adverse effects. Most of all, clini-
cians need to consider a broader range of symptoms
and individual patient priorities in adjusting medica-
tion dosages by suggesting medication strategies that
strike a better balance between motor and cognitive
symptoms.60 It is also important to consider premor-
bid personality and psychiatric history when making
clinical decisions. Future clinical treatment algorithms
may include information about specific gene polymor-
phisms that affect the dopamine system (so-called
“personalized medicine”). It may also be prudent to
consider exercise as an adjunct to dopamine therapy
to reduce motor symptoms to also minimize the over-
dose, because recent studies have shown promise using
balance training over six months61 and progressive
resistance exercise over two years.62
Cognitive functions, including reward-based learn-
ing, have been the major focus of research of the
dopamine overdose hypothesis.60 However, much less
is known about the neurobehavioral correlates of
these impairments and how they affect the instrumen-
tal activities of daily living. Dopamine dysregulation
syndrome is a dysfunction of the reward system in
patients with Parkinson’s disease who are on dopami-
nergic drugs: particularly dopamine agonists. Patients
with dopamine dysregulation syndrome exhibit evi-
dence of impulse control disorders.63 Further research
is needed to determine whether an excess of exoge-
nous dopamine release within the anteroventral
striatum and related cortical projections may be a
mechanistic factor underlying impulsive and/or risk-
taking behaviors in susceptible patients.
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